![]() XARELTO ®, in combination with aspirin, is indicated to reduce the risk of major thrombotic vascular events (myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of a vascular etiology) in adult patients with peripheral artery disease (PAD), including patients who have recently undergone a lower extremity revascularization procedure due to symptomatic PAD. XARELTO ®, in combination with aspirin, is indicated to reduce the risk of major cardiovascular events (cardiovascular death, myocardial infarction, and stroke) in adult patients with coronary artery disease (CAD). XARELTO ® is indicated for the prophylaxis of venous thromboembolism (VTE) and VTE-related death during hospitalization and post hospital discharge in adult patients admitted for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE, and not at high risk of bleeding. ![]() XARELTO ® is indicated for the prophylaxis of DVT, which may lead to PE in adult patients undergoing knee or hip replacement surgery. XARELTO ® is indicated for the reduction in the risk of recurrence of DVT and/or PE in adult patients at continued risk for recurrent DVT and/or PE after completion of initial treatment lasting at least 6 months. XARELTO ® is indicated for the treatment of pulmonary embolism (PE). XARELTO ® is indicated for the treatment of deep vein thrombosis (DVT). There are limited data on the relative effectiveness of XARELTO ® and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled. SSS occurring spontaneously or as a result of necessary drug therapy, with heart rate less than 40 bpm when a clear association between significant symptoms consistent with bradycardia and the actual presence of bradycardia has not been documented.XARELTO ® (rivaroxaban) is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (AF). In some patients, bradycardia is iatrogenic and will occur as a consequence of essential long-term drug therapy of a type and dosage for which there are no acceptable alternatives. SSS with documented symptomatic bradycardia, including frequent sinus pauses that produce symptoms. 5 Furthermore, there is no definitive way to distinguish patients with atrial fibrillation associated with sick sinus syndrome from patients with atrial fibrillation and normal sinus function this distinction is clinically important because treating atrial fibrillation with cardioversion or medications can have catastrophic consequences if the sinus node is inadequate. ![]() 2 If the patient is asymptomatic when ECG or ambulatory monitoring is performed, the dysrhythmias of the syndrome are often not present. 5 Symptoms of sick sinus syndrome may be variable, intermittent, and difficult to associate with ECG changes. 9 Some symptoms of patients with sick sinus syndrome (e.g., fatigue, irritability, memory loss, lightheadedness, palpitations, cognitive defects) are present in several other disorders that occur in elderly patients and may be misdiagnosed as those of senile dementia. The condition often goes undetected in the early stages because only sinus bradycardia may be present at its origin. ![]() The diagnosis of sick sinus syndrome may be difficult because of the slow and erratic course of the syndrome. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |